Evidence map›Paper›PMID 41797306›Full record

ArticleBritish journal of haematology2026

Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.

Simone Claudiani, Silvia Metelli, Afzal Khan, Guy Hannah, Jenny Byrne, Paolo Gallipoli, Simon J Bulley, Gillian A Horne, Kate Rothwell, Mhairi Copland and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Simone ClaudianiDepartment of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Imperial College London, London, UK.
Silvia MetelliCentre of Research in Epidemiology and Statistics (CRESS), University of Paris, INSERM, INRA, Paris, France.
Afzal KhanDepartment of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
Guy HannahDepartment of Haematology, King's College Hospital, King's College Hospital NHS Foundation Trust, London, UK.
Jenny ByrneCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Paolo GallipoliWellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
Simon J BulleyDepartment of Haematology, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK.
Gillian A HornePaul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Kate RothwellDepartment of Haematology, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK.
Mhairi CoplandPaul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Richard E ClarkDepartment of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Fiona FernandoDepartment of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Imperial College London, London, UK.
Andrew J InnesDepartment of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Imperial College London, London, UK.
Jane F ApperleyDepartment of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Imperial College London, London, UK.
Dragana MilojkovicDepartment of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The modern management of chronic myeloid leukaemia (CML) identifies a new therapeutic goal of treatment-free remission (TFR). Half of CML patients in durable deep molecular response (DMR) (MR

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRemission InductionTreatment InterruptionTreatment OutcomeYoung AdultProtein Kinase InhibitorsDMRprognostic scoreTFRTKI

Identifiers

PMID41797306
PMCPMC13176515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.